RecruitingNot ApplicableNCT07145489

Infrared Photobiomodulation in Humans With Epilepsy

An Open Label Pilot Study of Infrared Photobiomodulation in Humans With Epilepsy

Sponsor

Beth Israel Deaconess Medical Center

Enrollment

13 participants

Start Date

Nov 25, 2025

Study Type

INTERVENTIONAL

Conditions

Drug Resistant Epilepsy

Summary

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called photobiomodulation for people with drug resistant epilepsy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.